NCT04268303View on ClinicalTrials.gov

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia

PHASE3CompletedINTERVENTIONAL
Enrollment

380

Participants

Timeline

Start Date

January 24, 2020

Primary Completion Date

May 6, 2020

Study Completion Date

May 6, 2020

Conditions
AgitationSchizophreniaSchizo Affective DisorderSchizoaffective DisorderSchizophreniform Disorders
Interventions
DRUG

Sublingual film containing dexmedetomidine (BXCL501)

Sublingual film containing dexmedetomidine (BXCL501)

DRUG

Placebo Film

Placebo Film for BXCL501

Trial Locations (15)

20877

BioXcel Clinical Research Site, Gaithersburg

29407

BioXcel Clinical Research Site, Charleston

33016

BioXcel Clinical Research Site, Miami Lakes

60640

BioXcel Clinical Research Site, Chicago

72211

BioXcel Clinical Research Site, Little Rock

75080

BioXcel Clinical Research Site, Richardson

75115

BioXcel Clinical Research Site, DeSoto

78754

BioXcel Clinical Research Site, Cerritos

BioXcel Clinical Research Site, Austin

89102

BioXcel Clinical Research Site, Las Vegas

90230

BioXcel Clinical Research Site, Culver City

90806

BioXcel Clinical Research Site, Long Beach

92868

BioXcel Clinical Research Site, Orange

08009

BioXcel Clinical Research Site, Berlin

08053

BioXcel Clinical Research Site, Marlton

Sponsors
All Listed Sponsors
collaborator

Cognitive Research Corporation

INDUSTRY

lead

BioXcel Therapeutics Inc

INDUSTRY